Intensity Therapeutics, Inc. (INTS) AI Stock Analysis

• Market Cap: $20.96M
• Dividend Yield: N/A
• Average Volume (3M): 5.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: 46.41%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 60,064,964
• 10 Day Avg. Volume: 8,790,984
• 30 Day Avg. Volume: 5,112,980
• PEG Ratio: -0.04
• Price to Book (P/B): 8.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.61
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $5.00
• Price Target Upside: 1182.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.41 ▲(4.62% Upside)

The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, and material cash burn indicating continued reliance on external funding). Technicals also weigh on the score with bearish trend signals (below short-term moving averages and negative MACD). Valuation is neutral-to-weak because a negative P/E limits comparability and there is no dividend yield support.

Positive Factors

Low Leverage

Very low debt relative to rebuilt equity materially reduces financial risk and interest burden, giving management flexibility to fund clinical activities and pursue partnerships. This strengthens solvency and strategic optionality while the company remains pre-commercial.

Extended Runway from Capital Raises

Successful 2025 financings that extended runway into Q2 2027 reduce near-term funding pressure and permit reinitiating patient enrollment and potential Phase 3 starts. This continuity materially improves program advancement odds and negotiating leverage with partners.

Differentiated Oncology Pipeline

A focused strategy on locally delivered immunotherapies that aim to elicit systemic responses is a distinct clinical approach versus systemic agents. If clinical efficacy and safety are demonstrated, this could yield a durable competitive advantage and make the programs attractive to partners.

Negative Factors

No Commercial Revenue

The company lacks any repeatable revenue engine and remains loss-making, so long-term viability depends on successful clinical outcomes and subsequent commercialization. Until then, profit generation is uncertain and strategic choices remain financing-driven rather than revenue-driven.

Sustained Cash Burn

Persistent negative operating and free cash flow (~-$9.5M TTM) forces recurring external financing or partnerships to sustain trials. This constrains the pace and scope of development, increases dilution risk, and creates execution uncertainty over the medium term.

Nasdaq Compliance Risk

Ongoing listing compliance uncertainty elevates structural risk: potential delisting or reverse split can impair access to capital, reduce institutional interest, complicate partnerships, and signal fragility—adversely affecting long-term financing and credibility.

Intensity Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

How the Company Makes Money

Intensity Therapeutics, Inc. generates revenue primarily through partnerships, collaborations, and licensing agreements with pharmaceutical companies and research institutions. As a clinical-stage company, its revenue model is heavily reliant on securing funding through strategic alliances and collaborations that support its research and development activities. Additionally, the company may receive milestone payments and royalties upon successful commercialization of its therapies developed in collaboration with its partners. The company's financial success is contingent on the advancement of its drug candidates through clinical trials and eventual regulatory approval, which would enable it to license or co-develop its proprietary treatments with larger pharmaceutical companies.

Intensity Therapeutics, Inc. Financial Statement Overview

Summary

Pre-commercial profile with essentially no revenue, persistent net losses, and continued cash burn (TTM operating/free cash flow about -$9.5M). The balance sheet is a relative strength with very low debt (~$0.1M) and improved equity (~$7.2M), but the company remains funding-dependent until revenues scale and losses narrow materially.

Income Statement

The company continues to generate essentially no revenue, while losses remain persistent. TTM (Trailing-Twelve-Months) net loss improved versus 2024 (about $11.7M vs. $16.3M), but profitability is still deeply negative and the business has not yet demonstrated a repeatable revenue engine. The main strength is some narrowing of losses in the most recent period; the key weakness is the absence of revenue and ongoing operating deficits typical of an early-stage biotech.

Balance Sheet

Leverage is very low (TTM total debt about $0.1M against stockholders’ equity of about $7.2M), which reduces financial risk. Equity and assets improved materially versus 2024, indicating balance sheet rebuilding and/or capital raises. However, returns remain very weak (TTM return on equity is strongly negative), and the balance sheet has shown volatility over time (including negative equity in earlier years), which highlights funding dependence.

Cash Flow

Cash burn remains significant: TTM (Trailing-Twelve-Months) operating and free cash flow are both about -$9.5M, and free cash flow declined versus the prior period (negative growth). While burn improved from 2024 levels (less negative operating/free cash flow), the company still relies on external financing to sustain operations, and ongoing negative cash generation is the primary risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-147.00K	0.00	0.00	0.00
EBITDA	-9.22M	-16.27M	-10.09M	-7.50M	-7.88M	-6.03M
Net Income	-11.74M	-16.27M	-10.54M	-7.58M	-7.90M	-5.96M
Balance Sheet
Total Assets	9.59M	4.78M	17.30M	1.76M	5.22M	10.15M
Cash, Cash Equivalents and Short-Term Investments	7.07M	2.59M	14.78M	1.31M	4.54M	9.32M
Total Debt	118.00K	138.00K	158.00K	4.49M	2.34M	497.48K
Total Liabilities	2.36M	1.86M	4.13M	16.86M	13.90M	11.71M
Stockholders Equity	7.22M	2.92M	13.16M	-15.10M	-8.68M	-1.56M
Cash Flow
Free Cash Flow	-9.50M	-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
Operating Cash Flow	-9.50M	-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
Investing Cash Flow	0.00	6.35M	-6.02M	0.00	0.00	4.56M
Financing Cash Flow	13.79M	2.90M	20.47M	2.25M	2.05M	6.29M

Intensity Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.39
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Positive. The current price of 0.39 is above the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.41, and above the 200-day MA of 0.38, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 50.68 is Neutral, neither overbought nor oversold. The STOCH value of 41.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INTS.

Intensity Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	49 Neutral	$709.44K	-0.06	―	―	178.82%	-4121.10%
INTS	45 Neutral	$20.96M	-0.61	-334.12%	―	―	46.41%
BDRX	41 Neutral	$768.21K	-0.02	-60.37%	―	-100.00%	86.75%
OGEN	29 Underperform	$3.05M	-0.04	-168.95%	―	―	90.27%

Intensity Therapeutics, Inc. Corporate Events

Intensity Therapeutics Granted Nasdaq Compliance Extension

On December 5, 2025, Intensity Therapeutics, Inc. announced it received a 180-day extension from Nasdaq to comply with the minimum $1.00 bid price requirement, following an initial compliance period that ended on December 3, 2025. The extension allows the company until June 1, 2026, to meet the requirement, with plans to monitor stock prices and consider a reverse stock split if necessary to maintain its Nasdaq listing. This extension does not immediately affect the company’s stock listing, but failure to comply could lead to delisting, impacting stakeholders and market perception.

The most recent analyst rating on (INTS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Intensity Therapeutics Expands At-The-Market Offering

On December 4, 2025, Intensity Therapeutics, Inc. announced an increase in the capacity of its ‘at-the-market’ offering program to $30 million, aimed at enhancing financial flexibility. This expansion allows the company to access capital efficiently, though there is no obligation to issue shares, and any utilization will depend on market conditions and strategic priorities.

The most recent analyst rating on (INTS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.